Aberrant epi-transcriptomic alterations contribute to disease progression in breast cancer brain metastasis

21 juin - 11h00 - 12h30

Centre de recherche - Paris

Amphithéâtre Hélène Martel-Massignac (BDD)

11 rue Pierre et Marie Curie - 75005 Paris

Description

1.7 million women globally will face a diagnosis of breast cancer, almost 40% of whom will develop metastatic disease. Breast cancer brain metastasis are a frequent and aggressive form of metastatic spread, with treatment options limited for each of the clinically relevant molecular subtypes. Advanced breast cancer cells display exceptional plasticity, capable of adapting to sequential bouts of therapeutic pressure, as well as the vastly changing environmental landscape. To understand potential drivers and novel targets in brain metastasis we have undertaken multi methyl-omic studies, and identified HRD as a gained vulnerability beyond the classic germline mutations in BRCA1/2 and PALB2. Preliminary pre-clinical studies suggest targeting HRD with PARPi may be an effective strategy for this extended patient population.

Organisateurs

Research Director - DR2 Celine VALLOT

Institut Curie

Scientific Project Manager Iro Triantafyllakou

Institut Curie

Orateurs

Leonie Young

Department of Surgery, RCSI

Invité(es) par

Celine VALLOT

Institut Curie

Une question sur le séminaire ?

Research Director - DR2 Celine VALLOT

celine.vallot@curie.fr

Research Director - DR2 Celine VALLOT

celine.vallot@curie.fr

Scientific Project Manager Iro Triantafyllakou

iro.triantafyllakou@curie.fr